LAG-3 Fills a Complex Role in the Immune System
The LAG-3 pathway has emerged as the next target for the use of immune checkpoint inhibitors in oncology.
T-DXd Demonstrates Real-World Efficacy in Advanced Breast Cancer With Dynamic HER2 Expression
Disparities in Survival Outcomes Revealed With BluePrint and MammaPrint Subtyping in HR+/HER2– Breast Cancer
Dr Freeman on Mortality Differences Across Racial Groups in Male Patients With Breast Cancer
Dr Parsons on the Correlation Between Liquid Biopsy and HER2 Status in Breast Cancer
2 Clarke Drive Cranbury, NJ 08512